Prostate adenocarcinoma (PCa) is a leading cause of morbidity and mortality in males. RecentlyPeptide radioligand radionuclide therapy (PRLT) with alpha-emitter Actinium ( Ac) prostate specific membraneantigen (PSMA) has been shown to prolong survival and improve quality of life in both heavily pre-treatedmetastatic castration resistant prostate cancer (mCRPC) and chemotherapy-naïve patients. Visceral metastases,including lung metastases in PCa have been associated with reduced overall survival compared to bonemetastases. We aimed to report initial experience in the response of lung metastases treated with Ac-PSMA-617radioligand therapy (RLT) in metastatic prostate cancer.
MASERUMULE Letjie;
MOKOALA K;
BRUCHERTSEIFER Frank;
VORSTER Mariza;
REED Janet;
LAWAL I;
MORGENSTERN Alfred;
SATHEKGE Mike;
2022-12-20
SOC NUCLEAR MEDICINE INC
JRC128884
0161-5505 (online),
https://jnm.snmjournals.org/content/63/supplement_2/2550,
https://publications.jrc.ec.europa.eu/repository/handle/JRC128884,
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
